Paion (company)
| PAION AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | DE000A0B65S3 |
| founding | 2000 |
| Seat |
Aachen , Germany
|
| management |
|
| Number of employees | 39 (2018) |
| sales | 2.8 million euros (2018) |
| Branch | Pharma |
| Website | www.paion.com |
| As of December 31, 2018 | |
The PAION is a biopharmaceutical company headquartered in Aachen and a second site in Cambridge . It develops and markets drugs for the treatment of thrombotic and cardiovascular diseases as well as diseases of the central nervous system . The company focuses on indications with unmet medical needs. The company is listed on the CDAX .
history
The company was founded in July 2000 by Wolfgang and Mariola Söhngen. Co-founders were Franz A. Wirtz , A. Lamotte and W.-D. Schleuning. Desmoteplase was licensed by Schering AG in the year it was founded. The first financing round was completed with EUR 28.6 million. The second financing round was completed in 2001 with EUR 3.8 million.
Millennium's PS-519 was licensed in 2002, but returned in 2003. In 2004 Paion licensed the neuroprotective agent Enecadin from Nippon Shinyaku ; the contract was terminated by Paion in early 2008. In 2004, Paion also signed an agreement with Forest Laboratories to develop and commercialize Desmoteplase in the United States and Canada . In 2005, the company entered into an agreement with Lundbeck to develop and commercialize Desmoteplase in Europe, Japan and all countries outside the USA and Canada.
Paion went public in 2005. Around 1 million new shares were issued in 2006 as part of a capital increase.
The partner Forest ended the collaboration in 2007 and returned the Desmoteplase rights for North America. At the same time, the partner Lundbeck decided to further develop Desmoteplase and took over the North American rights. Paion received EUR 8 million from partner Lundbeck when the new license and development agreement came into force.
In 2008 Paion bought the rights to the anticoagulant Flovagatran from Trigen Limited; in the same year Paion took over CeNeS Pharmaceuticals plc. In late 2011, Paion announced a major restructuring. Financing should be secured until the summer of 2013 by waiving salaries and downsizing.
Research and Development
Stroke / blood clotting
Paion's most important stroke project so far has been Desmoteplase. Clinical development began in 2003, but suffered a setback due to the disappointing results of the Phase III DIAS-2 study . After further evaluations, however, Paion and Lundbeck declared that they wanted to continue the development.
In 2008, the development of the neuroprotective agent Enecadin was stopped. The company also announced that it had received evidence of the effectiveness of the anticoagulant ' Solulin ' in a Phase I study . Paion also acquired the worldwide rights to the anticoagulant Flovagatran from the British company Trigen Limited .
Pain / anesthesia
With the takeover of the CeNeS company, Paion is now also developing three medicinal substances for the treatment of pain or for use in anesthesia . A morphine - metabolite , morphine-6-glucuronide (M6G) is in phase III. A dose-finding study with the NMDA - antagonist CNS 5161 was conducted of 2007. 2020 was GABA A - partial agonist Remimazolam (CNS 7056) approved in Japan and the United States.
Web links
Individual evidence
- ↑ a b Annual Report 2018. (pdf) In: paion.com. Retrieved October 5, 2019 .
- ↑ Paion completes acquisition of CeNeS
- ↑ Press release of December 19, 2011 (PDF; 39 kB) ( page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.
